Table 1 Trial characteristics, exposure, baseline participant covariates, and outcomes across trials and treatment groups

From: Risk of weight gain for specific antipsychotic drugs: a meta-analysis

Study Duration Total subjects Antipsychotic Total exposure: median (max) % with weight gain drugs Age: mean (SD) PANSS: mean (SD) % White % Black % Female Outcome: % with 7% weight gain
Baseline characteristics
1 Variable (≤11 mts) 206 Paliperidone: 50.5% 3.06 (21.30) 9.6 39 (11) 92.9 (11.2) 60 8 44 18.27
Placebo: 49.5% 0 10.8 37 (10) 94 (11.1) 60 9 37 11.76
2 6 weeks 114 Paliperidone: 66.7% 2.09 (4.50) 6.6 70 (5) 91.8 (9.7) 99 0 74 0
Placebo: 33.3% 0 2.6 69 (3) 94.3 (9) 100 0 71 2.63
3 6 weeks 627 Olanzapine: 20.1% 0.84 (1.04) 2.4 36 (11) 93 (10.7) 87 0 54 22.22
Paliperidone: 59.8% 2.46 (4.08) 2.1 37 (11) 94 (11.1) 86 0 46 10.93
Placebo: 20.1% 0 2.4 37 (11) 94.1 (10.7) 84 0 48 3.17
4 6 weeks 438 Olanzapine: 24.9% 0.56 (1.92) 13.8 40 (11) 94.9 (12.3) 42 0 19 17.43
Paliperidone: 51.1% 1.68 (3.84) 13.8 42 (10) 93.2 (11.7) 41 0 31 10.27
Placebo: 24% 0 21.9 42 (11) 93.5 (11.9) 48 0 22 5.71
5 6 weeks 614 Olanzapine: 20.7% 0.84 (0.94) 4.7 37 (10) 93.4 (12.2) 48 23 24 19.69
Paliperidone: 59.3% 2 (4.58) 11.5 37 (11) 92.6 (12.6) 49 21 36 10.99
Placebo: 20% 0 8.9 37 (11) 93.8 (12.6) 51 21 30 5.69
6a 6 weeks 316 Pali: 66.1% 3.52 (8.00) 19.6 37 (10) 94.2 (12.9) 43 22 34 6.70
Placebo: 33.9% 0 19.6 37 (11) 91.6 (12.5) 50 19 37 1.87
7a 6 weeks 310 Paliperidone: 69.4% 3.28 (4.00) 24.2 38 (9) 92.2 (13.5) 52 18 45 6.98
Placebo: 30.6% 0 28.4 38 (10) 91.7 (12) 52 18 41 1.05
8a 18 months 342 Olanzapine: 50% 0.84 (3.9) 13.5 41 (11) 74.3 (19) 65 32 27 11.11
Risperidone: 50% 0.42 (1.23) 20.5 41 (11) 76.8 (16.8) 66 30 27 5.26
9b Recurrence prevention 408 Paliperidone: 50.2% 1.78 (6.67) 10.7 39 (11) 70 (18.3) 65 18 47 5.85
Placebo: 49.8% 0 10.8 39 (11) 70.6 (17.6) 66 18 45 2.46
10b 53 weeks 748 Paliperidone: 50.7% 4.33 (8.50) 9 41 (12) 82 (12.7) 92 0 43 13.19
Risperidone: 49.3% 0.38 (4.78) 8.4 41 (12) 81.2 (13.4) 92 0 38 14.09
11b 13 weeks 387 Paliperidone: 75.5% 1.33 (4.00) 15.8 40 (11) 90.4 (11.3) 40 41 32 12.33
Placebo: 24.5% 0 20 40 (11) 93.9 (12.9) 38 41 27 9.47
12b 13 weeks 515 Paliperidone: 75.5% 1.33 (2.67) 11.3 40 (11) 90.8 (12) 67 29 32 12.34
Placebo: 24.5% 0 7.9 40 (11) 90.7 (12.3) 66 29 38 7.14
13b 13 weeks 651 Paliperidone: 74.8% 2 (4.00) 7.6 39 (11) 87.3 (11.5) 53 31 32 11.29
Placebo: 25.2% 0 6.7 39 (11) 86.8 (10.2) 54 32 34 4.27
14b 9 weeks 247 Paliperidone: 66% 1 (2.00) 8 38 (10) 94.4 (11.5) 70 17 31 5.52
Placebo: 34% 0 7.1 39 (11) 95.7 (12.7) 73 17 35 3.57
All studies 5923 Olanzapine: 9% 0.84 (3.9) 8.8 39 (11) 87.5 (17.1) 62 16 31 17.07
    Paliperidone: 58.8% 2 (21.3) 11.1 39 (12) 89.3 (13.8) 62 18 38 10.40
    Placebo: 23.1% 0 12.1 40 (12) 89 (15.1) 60 18 38 4.82
    Risperidone: 9.1% 0.40 (4.78) 12.2 41 (12) 79.8 (14.7) 84 9 34 11.30
  1. Exposure is in 10 g chlorpromazine equivalent units (i.e., 100,100 mg chlorpromazine equivalents)
  2. WG weight gain, PANSS positive and negative syndrome scale
  3. aTrial measuring adherence through pill counts
  4. bTrial measuring adherence with injectable treatment drugs